Wall Street brokerages expect that XOMA Corp (NASDAQ:XOMA) will announce ($0.20) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for XOMA’s earnings. The lowest EPS estimate is ($0.36) and the highest is $0.12. XOMA posted earnings per share of $0.21 during the same quarter last year, which would indicate a negative year over year growth rate of 195.2%. The company is scheduled to announce its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that XOMA will report full year earnings of ($0.79) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.66). For the next financial year, analysts anticipate that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.84) to ($0.27). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow XOMA.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.06. XOMA had a net margin of 40.44% and a negative return on equity of 670.15%. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $3.69 million.
In other news, SVP Thomas M. Burns sold 11,000 shares of the business’s stock in a transaction dated Friday, April 27th. The stock was sold at an average price of $24.71, for a total transaction of $271,810.00. Following the completion of the sale, the senior vice president now owns 14,900 shares in the company, valued at approximately $368,179. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James R. Neal sold 24,000 shares of the business’s stock in a transaction dated Friday, April 27th. The stock was sold at an average price of $24.51, for a total value of $588,240.00. Following the sale, the chief executive officer now owns 24,678 shares of the company’s stock, valued at approximately $604,857.78. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. Allianz Asset Management GmbH grew its holdings in shares of XOMA by 32.7% during the 1st quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 3,020 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of XOMA during the 1st quarter worth about $243,000. Tibra Equities Europe Ltd purchased a new stake in shares of XOMA during the 1st quarter worth about $283,000. Spark Investment Management LLC purchased a new stake in shares of XOMA during the 1st quarter worth about $904,000. Finally, ClariVest Asset Management LLC purchased a new stake in shares of XOMA during the 1st quarter worth about $380,000. Institutional investors and hedge funds own 40.63% of the company’s stock.
Shares of NASDAQ XOMA traded down $0.25 on Thursday, reaching $21.76. 14,294 shares of the company traded hands, compared to its average volume of 153,541. XOMA has a fifty-two week low of $6.10 and a fifty-two week high of $37.25. The company has a debt-to-equity ratio of 2.59, a current ratio of 7.26 and a quick ratio of 7.26. The company has a market cap of $179.14 million, a P/E ratio of 22.21 and a beta of 2.95.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.